My biography – used for external lectures and introductions.

Rob joined Wellcome on Valentine’s day in 1990, following BA/DPhil degrees at University of Oxford and Post Doc at Ben May Institute, University of Chicago. His subsequent career navigated changes, mergers and acquisitions and positions of increasing responsibility to become a Scientific Leader and elected GSK Fellow.  Early career charted significant contributions to six development candidates in antivirals (HIV/HBV/Herpes), iNOS and Factor Xa, before a move to early stage discovery (2006) fulfilling leadership roles numerous H2L programs, using diverse technologies including HTS, fragments, focussed & designed screens and DNA-encoded libraries.  Substantive transnational working included close ties with the GSK Diseases of the Developing World group in Spain encompassing leadership of several H2L programmes, plus mentoring and SAB roles. Expertise in Physical Properties and the Property Forecast Index were developed in a productive partnership with Alan Hill spanning many years, instrumental in setting new standards in drug discovery with chromatographic methods.  Appointed/co-opted to numerous GSK cross-disciplinary initiatives and communities including in silico predictive modelling, DMPK, Physical Chemsitry, Stability and Safety.   Author/inventor on 100 publications/ patent applications and an honorary visiting Professor, University of St Andrews.

Rob took early retirement from GSK in July 2019 and set up Blue Burgundy to pursue medicinal chemistry consulting and educational interests.